PE20120218A1 - Compuestos para el tratamiento de trastornos metabolicos - Google Patents
Compuestos para el tratamiento de trastornos metabolicosInfo
- Publication number
- PE20120218A1 PE20120218A1 PE2011001638A PE2011001638A PE20120218A1 PE 20120218 A1 PE20120218 A1 PE 20120218A1 PE 2011001638 A PE2011001638 A PE 2011001638A PE 2011001638 A PE2011001638 A PE 2011001638A PE 20120218 A1 PE20120218 A1 PE 20120218A1
- Authority
- PE
- Peru
- Prior art keywords
- piperidin
- alkyl
- compounds
- halo
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE Z ES C(O)OR4, HETEROARILO, ENTRE OTROS, EN DONDE R4 ES ALQUILO(C2-C6) O CICLOALQUILO(C3-C6); X ES O, NR7 O CR6R66, EN DONDE R6 Y R66 SON CADA UNO H, F O ALQUILO(C1-C4); R7 ES H O ALQUILO(C1-C4); Y ES ALQUILENO(C2-C4) OPCIONALMENTE SUSTITUIDO CON F O METILO; A ES FENILO O UN ANILLO HETEROAROMATICO DE 6 MIEMBROS QUE CONTIENE 1 A 2 ATOMOS DE N; R1 ES H, HALO, CN, ALQUILO(C1-C4) O HALOALQUILO(C1-C4); R2 ES FENILO SUSTITUIDO OPCIONALMENTE CON HALO, PIRIDILO SUSTITUIDO OPCIONALMENTE CON HALO O METILO, ENTRE OTROS; p ES 1 O 2; q ES 1 O 2. SON COMPUESTOS PREFERIDOS: 1-[(3S,4S)-4-AMINO-1-(5-{(R)-3-[1-(5-CLOROPIRIMIDIN-2-IL)PIPERIDIN-4-IL]BUTOXI}PIRIMIDIN-2-IL)PIRROLIDIN-3-IL]PIPERIDIN-2-ONA, 1-[(3S,4S)-4-AMINO-1-(6-{(R)-3-[1-(3-ISOPROPIL-[1,2,4]OXADIAZOL-5-IL)PIPERIDIN-4-IL]BUTOXI}PIRIMIDIN-4-IL)PIRROLIDIN-3-IL]PIPERIDIN-2-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR ACOPLADO A PROTEINA G 119 (GPR119) SIENDO UTILES EN EL TRATAMIENTO DE DIABETES TIPO II, OBESIDAD, SINDROME METABOLICO, HIPERLIPIDEMIA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0904285.4A GB0904285D0 (en) | 2009-03-12 | 2009-03-12 | Compounds for the treatment of metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120218A1 true PE20120218A1 (es) | 2012-03-19 |
Family
ID=40600947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001638A PE20120218A1 (es) | 2009-03-12 | 2010-03-12 | Compuestos para el tratamiento de trastornos metabolicos |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120059014A1 (es) |
EP (1) | EP2406251A1 (es) |
JP (1) | JP2012520283A (es) |
KR (1) | KR20110133045A (es) |
CN (1) | CN102395578A (es) |
AU (1) | AU2010222672A1 (es) |
BR (1) | BRPI1009783A2 (es) |
CA (1) | CA2754791A1 (es) |
CL (1) | CL2011002182A1 (es) |
EA (1) | EA201190207A1 (es) |
GB (1) | GB0904285D0 (es) |
IL (1) | IL215050A0 (es) |
MA (1) | MA33241B1 (es) |
MX (1) | MX2011009493A (es) |
PE (1) | PE20120218A1 (es) |
SG (1) | SG174363A1 (es) |
WO (1) | WO2010103334A1 (es) |
ZA (1) | ZA201107449B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007007751A1 (de) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102007035333A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
US8293729B2 (en) | 2009-06-24 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
GB201006167D0 (en) * | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
WO2012066077A1 (en) | 2010-11-18 | 2012-05-24 | Prosidion Limited | 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders |
GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
CN103649076B (zh) * | 2011-05-13 | 2015-09-09 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
EA031618B1 (ru) | 2011-06-09 | 2019-01-31 | Ризен Фармасьютикалз Са | Соединения-модуляторы gpr-119 |
GB2497351A (en) * | 2011-12-09 | 2013-06-12 | Prosidion Ltd | Compounds useful as GPR119 agonists |
EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2016131198A1 (en) * | 2015-02-18 | 2016-08-25 | Eli Lilly And Company | Pyrazole compounds |
EP4219449A3 (en) | 2016-03-16 | 2023-10-11 | Kura Oncology, Inc. | Substituted indole derivatives and methods of preparation thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
JP2002523090A (ja) | 1998-09-01 | 2002-07-30 | ビーエーエスエフ アクチェンゲゼルシャフト | 異種gタンパク質共役受容体の増強された機能的発現 |
US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
US8207147B2 (en) | 2003-12-24 | 2012-06-26 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
US20080312281A1 (en) | 2004-12-24 | 2008-12-18 | Matthew Colin Thor Fyfe | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes |
WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
JP5114395B2 (ja) | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Gpcrアゴニスト |
AU2006264651A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
EP1907384A2 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
US20090221639A1 (en) | 2006-04-06 | 2009-09-03 | Lisa Sarah Bertram | Heterocyclic GPCR Agonists |
GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
WO2008070692A2 (en) * | 2006-12-06 | 2008-06-12 | Smithkline Beecham Corporation | Bicyclic compounds and use as antidiabetics |
CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
ATE523507T1 (de) | 2007-01-04 | 2011-09-15 | Prosidion Ltd | Piperidin-gpcr-agonisten |
PE20081659A1 (es) | 2007-01-04 | 2008-10-24 | Prosidion Ltd | Agonistas de gpcr |
JP2010514832A (ja) | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | ピペリジンgpcrアゴニスト |
US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
CN101754962B (zh) | 2007-07-19 | 2013-12-25 | 赛马拜制药公司 | 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物 |
JP2010539152A (ja) | 2007-09-10 | 2010-12-16 | プロシディオン・リミテッド | 代謝障害の治療のための化合物 |
US8568899B2 (en) | 2007-10-18 | 2013-10-29 | Jx Nippon Mining & Metals Corporation | Metal covered polyimide composite, process for producing the composite, and process for producing electronic circuit board |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
CN101621337B (zh) | 2008-06-30 | 2013-08-07 | 华为技术有限公司 | 一种时延调节装置与方法 |
WO2010004343A1 (en) | 2008-07-10 | 2010-01-14 | Prosidion Limited | Piperidinyl gpcr agonists |
GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
CN102089301A (zh) | 2008-07-10 | 2011-06-08 | 普洛希典有限公司 | 哌啶gpcr激动剂 |
GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
-
2009
- 2009-03-12 GB GBGB0904285.4A patent/GB0904285D0/en not_active Ceased
-
2010
- 2010-03-12 WO PCT/GB2010/050441 patent/WO2010103334A1/en active Application Filing
- 2010-03-12 PE PE2011001638A patent/PE20120218A1/es not_active Application Discontinuation
- 2010-03-12 EP EP10709053A patent/EP2406251A1/en not_active Withdrawn
- 2010-03-12 CA CA2754791A patent/CA2754791A1/en not_active Abandoned
- 2010-03-12 EA EA201190207A patent/EA201190207A1/ru unknown
- 2010-03-12 AU AU2010222672A patent/AU2010222672A1/en not_active Abandoned
- 2010-03-12 CN CN2010800171471A patent/CN102395578A/zh active Pending
- 2010-03-12 SG SG2011065802A patent/SG174363A1/en unknown
- 2010-03-12 US US13/255,531 patent/US20120059014A1/en not_active Abandoned
- 2010-03-12 JP JP2011553533A patent/JP2012520283A/ja active Pending
- 2010-03-12 MA MA34245A patent/MA33241B1/fr unknown
- 2010-03-12 MX MX2011009493A patent/MX2011009493A/es unknown
- 2010-03-12 KR KR1020117024019A patent/KR20110133045A/ko not_active Application Discontinuation
- 2010-03-12 BR BRPI1009783A patent/BRPI1009783A2/pt not_active Application Discontinuation
-
2011
- 2011-09-05 CL CL2011002182A patent/CL2011002182A1/es unknown
- 2011-09-08 IL IL215050A patent/IL215050A0/en unknown
- 2011-10-11 ZA ZA2011/07449A patent/ZA201107449B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201190207A1 (ru) | 2012-04-30 |
CL2011002182A1 (es) | 2012-03-30 |
BRPI1009783A2 (pt) | 2016-03-08 |
AU2010222672A1 (en) | 2011-11-03 |
WO2010103334A1 (en) | 2010-09-16 |
GB0904285D0 (en) | 2009-04-22 |
SG174363A1 (en) | 2011-10-28 |
JP2012520283A (ja) | 2012-09-06 |
CN102395578A (zh) | 2012-03-28 |
CA2754791A1 (en) | 2010-09-16 |
ZA201107449B (en) | 2012-06-27 |
EP2406251A1 (en) | 2012-01-18 |
US20120059014A1 (en) | 2012-03-08 |
MA33241B1 (fr) | 2012-05-02 |
IL215050A0 (en) | 2011-11-30 |
KR20110133045A (ko) | 2011-12-09 |
MX2011009493A (es) | 2011-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120218A1 (es) | Compuestos para el tratamiento de trastornos metabolicos | |
PE20081659A1 (es) | Agonistas de gpcr | |
PE20090449A1 (es) | Agonistas de receptor acoplado a proteina g gpr119 de piridona | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
AR064736A1 (es) | Agonistas de gpcr | |
PE20110329A1 (es) | Agonistas del receptor acoplado a la proteina g piperidinilo | |
PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20121045A1 (es) | Agonista de gpr119 | |
PE20091527A1 (es) | Derivados de piridazinona | |
PE20090222A1 (es) | Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119 | |
PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
PE20121336A1 (es) | Nuevos compuestos triciclicos | |
CL2008002159A1 (es) | Compuestos derivados de n-(((1r, 4r)-4-aminociclohexil)metil) sulfonaminas sustituidas con heterociclos, antagonistas del receptor npy y5; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar anorexia y obesidad. | |
PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
PE20090157A1 (es) | Derivados de pirimidinona como moduladores del receptor acoplado a proteina g 119 (gpr119) | |
PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
HN2010002772A (es) | Compuestos organicos nuevo titulo de la invencion: derivados de 2-(3-piridil)-indol sustituido y composicionesfarmaceuticas de los mismos. (bajo el escrito 2013-000513 de fecha 27 de febrero de 2013) solicitado por esta oficina de registro | |
PE20120399A1 (es) | Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119 | |
PE20080676A1 (es) | Derivados de indol como antagonistas del receptor de glucagon | |
PE20091324A1 (es) | Compuestos espiro como antagonistas del receptor npy y5 | |
PE20110341A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
UY32884A (es) | 1-sustituido-4-(5-(fenil o heteroaril)metoxi)-pirimidin-2-il)piperazinas y piperidinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |